World Health Organization (2006) Antiretroviral drugs for treating pregnant women and preventing HIV infection in infant: towards universal access. Recommendations for a public health approach. Available: http://www.who.int/hiv/pub/guidelines/pm？tctguidelines3.pdf. Accessed 4 September 2009.
[2]
Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, et al. (1999) Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 354: 795–802.
[3]
Arrive E, Dabis F (2008) Prophylactic antiretroviral regimens for prevention of mother-to-child transmission of HIV in resource-limited settings. Curr Opin HIV AIDS 3: 161–165.
[4]
Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanuwong C, Kantipong P, et al. (2004) Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 351: 229–240.
[5]
Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, et al. (2007) Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 356: 135–147.
[6]
Lockman S (2008) Prevention of mother-to-child transmission, drug resistance, and implications for response to therapy. Curr Opin HIV AIDS 3: 166–172.
[7]
Dao H, Mofenson LM, Ekpini R, Gilks CF, Barnhart M, et al. (2007) International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update. Am J Obstet Gynecol 197: S42–S55.
[8]
World Health Organization, UNAIDS, Unicef (2008) Towards universal access. Scaling up priority HIV/AIDS interventions in the health sector. Available: http://www.who.int/hiv/pub/2008progressr？eport/en/. Accessed 4 September 2009.
[9]
Kilewo C, Karlsson K, Ngarina M, Massawe A, Lyamuya E, et al. (2009) Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus Study. J Acquir Immune Defic Syndr. In press.
[10]
Lehman DA, Chung MH, Mabuka JM, John-Stewart GC, Kiarie J, et al. (2009) Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission. J Acquir Immune Defic Syndr 51: 522–529.
[11]
Eshleman SH, Hoover DR, Hudelson SE, Chen S, Fiscus SA, et al. (2006) Development of nevirapine resistance in infants is reduced by use of infant-only single-dose nevirapine plus zidovudine postexposure prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Infect Dis 193: 479–481.
[12]
McIntyre JA, Hopley M, Moodley D, Eklund M, Gray GE, et al. (2009) Efficacy of short-course AZT+3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission. PLoS Med 6: e1000172. doi:10.1371/journal.pmed.1000172.
[13]
McIntyre J, Martinson N, Gray G, Hopley M, Kimura T, et al. (2005) Addition of short course Combivir (CBV) to single dose Viramune (sdNVP) for the prevention of mother to child transmission (pMTCT) of HIV-1 can significantly decrease the subsequent development of maternal and paediatric NNRTI-resistant virus TuFo0204.
[14]
Chaix ML, Ekouevi DK, Rouet F, Tonwe-Gold B, Viho I, et al. (2006) Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire. J Infect Dis 193: 482–487.
[15]
Chi BH, Sinkala M, Mbewe F, Cantrell RA, Kruse G, et al. (2007) Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet 370: 1698–1705.
